{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T03:26:05Z","timestamp":1775791565479,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["New Microbes and New Infections"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.nmni.2021.100895","type":"journal-article","created":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T12:46:40Z","timestamp":1620391600000},"page":"100895","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019"],"prefix":"10.1016","volume":"42","author":[{"given":"M.","family":"Shabani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Sadegh Ehdaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Dowran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmni.2021.100895_bib1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0065-3527(06)66005-3","article-title":"The molecular biology of coronaviruses","volume":"66","author":"Masters","year":"2006","journal-title":"Adv Virus Res"},{"issue":"1","key":"10.1016\/j.nmni.2021.100895_bib2","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1186\/s12879-019-4284-9","article-title":"Prevalence of hepatitis C infection among the general population and high-risk groups in the EU\/EEA: a systematic review update","volume":"19","author":"Han","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"4p2","key":"10.1016\/j.nmni.2021.100895_bib3","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1600-6143.2010.03037.x","article-title":"Liver transplantation in the United States, 1999\u20132008","volume":"10","author":"Thuluvath","year":"2010","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.nmni.2021.100895_bib4","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","article-title":"Epidemiology of viral hepatitis and hepatocellular carcinoma","volume":"142","author":"El-Serag","year":"2012","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.nmni.2021.100895_bib5","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.nmni.2021.100895_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1478-3231.2011.02537.x","article-title":"The global health burden of hepatitis C virus infection","volume":"31","author":"Negro","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.nmni.2021.100895_bib7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1478-3231.2011.02539.x","article-title":"A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel","volume":"31","author":"Cornberg","year":"2011","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.nmni.2021.100895_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-18296-9","article-title":"The epidemiology of hepatitis C virus in Iran: systematic review and meta-analyses","volume":"8","author":"Mahmud","year":"2018","journal-title":"Sci Rep"},{"issue":"7940","key":"10.1016\/j.nmni.2021.100895_bib9","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(75)90234-2","article-title":"Clinical and serological analysis of transfusion-associated hepatitis","volume":"306","author":"Alter","year":"1975","journal-title":"Lancet"},{"issue":"4902","key":"10.1016\/j.nmni.2021.100895_bib10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome","volume":"244","author":"Choo","year":"1989","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.nmni.2021.100895_bib11","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1073\/pnas.87.6.2057","article-title":"Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups","volume":"87","author":"Miller","year":"1990","journal-title":"Proc Nat Acad Sci"},{"issue":"12","key":"10.1016\/j.nmni.2021.100895_bib12","doi-asserted-by":"crossref","first-page":"9984","DOI":"10.1128\/JVI.73.12.9984-9991.1999","article-title":"Hyperphosphorylation of the hepatitis C virus NS5A protein requires an active NS3 protease, NS4A, NS4B, and NS5A encoded on the same polyprotein","volume":"73","author":"Neddermann","year":"1999","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.nmni.2021.100895_bib13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jhep.2013.08.018","article-title":"Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience","volume":"60","author":"Coilly","year":"2014","journal-title":"J Hepatol"},{"issue":"13","key":"10.1016\/j.nmni.2021.100895_bib14","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"New England J Med"},{"issue":"3","key":"10.1016\/j.nmni.2021.100895_bib15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"New England J Med"},{"issue":"7294","key":"10.1016\/j.nmni.2021.100895_bib16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.nmni.2021.100895_bib17","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.coviro.2013.06.014","article-title":"Antiviral activity and resistance of HCV NS5A replication complex inhibitors","volume":"3","author":"Gao","year":"2013","journal-title":"Curr Opin Virol"},{"issue":"4","key":"10.1016\/j.nmni.2021.100895_bib18","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.nmni.2021.100895_bib19","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","article-title":"Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"Wyles","year":"2015","journal-title":"New England J Med"},{"key":"10.1016\/j.nmni.2021.100895_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2020.02.001","article-title":"Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.nmni.2021.100895_bib21","first-page":"93","volume":"vol. 105","author":"Tortorici","year":"2019"},{"issue":"7798","key":"10.1016\/j.nmni.2021.100895_bib22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.nmni.2021.100895_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.nmni.2021.100895_bib24","article-title":"The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2","author":"Sacramento","year":"2020","journal-title":"bioRxiv"},{"issue":"6","key":"10.1016\/j.nmni.2021.100895_bib25","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.arcmed.2020.04.018","article-title":"Sofosbuvir as repurposed antiviral drug against COVID-19: why were we convinced to evaluate the drug in a registered\/approved clinical trial?","volume":"51","author":"Sayad","year":"2020","journal-title":"Archiv Med Res"},{"issue":"1","key":"10.1016\/j.nmni.2021.100895_bib26","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)","volume":"14","author":"Dong","year":"2020","journal-title":"Drug Dis Therapeut"},{"issue":"1","key":"10.1016\/j.nmni.2021.100895_bib27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1515\/jtim-2017-0007","article-title":"Direct acting anti-hepatitis C virus drugs: clinical pharmacology and future direction","volume":"5","author":"Geddawy","year":"2017","journal-title":"J Translat Inter Med"},{"issue":"1","key":"10.1016\/j.nmni.2021.100895_bib28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/1060028015610342","article-title":"Daclatasvir: a NS5A replication complex inhibitor for hepatitis C infection","volume":"50","author":"Smith","year":"2016","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.nmni.2021.100895_bib29","article-title":"A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing.","author":"O'Meara","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.nmni.2021.100895_bib30","doi-asserted-by":"crossref","first-page":"117652","DOI":"10.1016\/j.lfs.2020.117652","article-title":"In silico studies on therapeutic agents for COVID-19: drug repurposing approach","author":"Shah","year":"2020","journal-title":"Life Sci"},{"issue":"10","key":"10.1016\/j.nmni.2021.100895_bib31","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s40265-014-0247-z","article-title":"Sofosbuvir: a review of its use in patients with chronic hepatitis","volume":"74","author":"Keating","year":"2014","journal-title":"C Drugs."},{"issue":"12","key":"10.1016\/j.nmni.2021.100895_bib32","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1586\/14787210.2013.855126","article-title":"Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection","volume":"11","author":"Rodr\u00edguez-Torres","year":"2013","journal-title":"Exp Rev Anti-Infect Ther"},{"issue":"45","key":"10.1016\/j.nmni.2021.100895_bib33","doi-asserted-by":"crossref","first-page":"34337","DOI":"10.1074\/jbc.M110.161802","article-title":"Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977","volume":"285","author":"Murakami","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nmni.2021.100895_bib34","article-title":"No resistance detected in four phase 3 clinical studies in HCV genotype 1-6 of Sofosbuvir+ ribavirin with or without peginterferon: 1843","volume":"58","author":"Svarovskaia","year":"2013","journal-title":"Hepatology"},{"issue":"20","key":"10.1016\/j.nmni.2021.100895_bib35","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"New England J Med"},{"issue":"20","key":"10.1016\/j.nmni.2021.100895_bib36","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"New England J Med"},{"key":"10.1016\/j.nmni.2021.100895_bib37","article-title":"All-oral therapy with sofosbuvir plus ribavirin for the treatment of Hcv Genotype 1, 2, and 3 infection in patients co-infected with Hiv (photon-1): 212","volume":"58","author":"Sulkowski","year":"2013","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.nmni.2021.100895_bib38","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/gutjnl-2013-305771","article-title":"New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C","volume":"63","author":"Mari\u00f1o","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.nmni.2021.100895_bib39","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1016\/j.dld.2014.09.026","article-title":"Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies","volume":"46","author":"Mangia","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.nmni.2021.100895_bib40","series-title":"Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase","author":"Chien","year":"2020"},{"key":"10.1016\/j.nmni.2021.100895_bib41","article-title":"Nucleotide analogues as inhibitors of SARS-CoV polymerase","author":"Ju","year":"2020","journal-title":"BioRxiv"},{"issue":"2","key":"10.1016\/j.nmni.2021.100895_bib42","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01389-18","article-title":"Beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication","volume":"63","author":"Ferreira","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.nmni.2021.100895_bib43","article-title":"The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2","author":"Sacramento","year":"2020","journal-title":"bioRxiv"},{"issue":"2","key":"10.1016\/j.nmni.2021.100895_bib44","first-page":"239","article-title":"Sofosbuvir as a potential option for the treatment of COVID-19","volume":"91","author":"Nourian","year":"2020","journal-title":"Acta Bio Medica: Atenei Parmensis"},{"key":"10.1016\/j.nmni.2021.100895_bib45","doi-asserted-by":"crossref","first-page":"104708","DOI":"10.1016\/j.antiviral.2020.104708","article-title":"Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro","volume":"175","author":"Dragoni","year":"2020","journal-title":"Antiviral Res"}],"container-title":["New Microbes and New Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2052297521000597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2052297521000597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:02:32Z","timestamp":1761854552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2052297521000597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":45,"alternative-id":["S2052297521000597"],"URL":"https:\/\/doi.org\/10.1016\/j.nmni.2021.100895","relation":{},"ISSN":["2052-2975"],"issn-type":[{"value":"2052-2975","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019","name":"articletitle","label":"Article Title"},{"value":"New Microbes and New Infections","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmni.2021.100895","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100895"}}